A detailed history of Hms Capital Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hms Capital Management, LLC holds 597 shares of VRTX stock, worth $269,229. This represents 0.14% of its overall portfolio holdings.

Number of Shares
597
Previous 597 -0.0%
Holding current value
$269,229
Previous $279,000 0.72%
% of portfolio
0.14%
Previous 0.15%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $48,735 - $54,546
-155 Reduced 20.61%
597 $210,000
Q4 2022

Jan 23, 2023

SELL
$285.76 - $321.48 $5,715 - $6,429
-20 Reduced 2.59%
752 $0
Q2 2022

Jul 27, 2022

BUY
$234.96 - $292.55 $181,389 - $225,848
772 New
772 $218,000
Q3 2021

Nov 02, 2021

SELL
$181.39 - $202.99 $230,365 - $257,797
-1,270 Closed
0 $0
Q4 2020

Jan 29, 2021

SELL
$207.01 - $276.09 $888,900 - $1.19 Million
-4,294 Reduced 77.17%
1,270 $300,000
Q3 2020

Oct 20, 2020

SELL
$255.65 - $303.1 $83,341 - $98,810
-326 Reduced 5.53%
5,564 $1.51 Million
Q2 2020

Jul 31, 2020

BUY
$225.48 - $295.8 $1.1 Million - $1.45 Million
4,888 Added 487.82%
5,890 $1.71 Million
Q4 2019

Jan 29, 2020

BUY
$166.71 - $223.91 $167,043 - $224,357
1,002 New
1,002 $219,000
Q3 2019

Oct 15, 2019

SELL
$166.23 - $187.09 $166,562 - $187,464
-1,002 Closed
0 $0
Q2 2019

Jul 12, 2019

BUY
$164.61 - $190.37 $164,939 - $190,750
1,002 New
1,002 $184,000
Q1 2019

Apr 24, 2019

SELL
$163.73 - $194.7 $406,377 - $483,245
-2,482 Closed
0 $0
Q2 2018

Aug 06, 2018

BUY
$145.72 - $169.96 $361,677 - $421,840
2,482 New
2,482 $422,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Hms Capital Management, LLC Portfolio

Follow Hms Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hms Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hms Capital Management, LLC with notifications on news.